Transition-Metal Complexes for Cancer Therapy and Photodynamic Applications
This community designs and synthesizes metal-based compounds, primarily involving platinum, ruthenium, and iridium, to treat cancers such as ovarian, breast, and bladder carcinoma, or to generate reactive oxygen species for photodynamic therapy.
The research focuses on the synthesis of coordination complexes, including iridium(III) and ruthenium(III) species, often utilizing Schiff base ligands. A significant portion of the work addresses platinum-based chemotherapy, specifically investigating mechanisms of cisplatin resistance and developing alternative anticancer agents. Photodynamic therapy is a major application area, with extensive study of singlet oxygen generation and photosensitizer design. The work also includes structural characterization via crystallography and computational modeling through molecular docking to understand interactions with DNA and cancer cells.
The largest share of the community's output is found in ruthenium research, accounting for 30.4% of all ruthenium research, and 10,721 papers here. Platinum follows with 24.0% of its research, and iridium with 20.2%.
The community comprises 46,909 papers, published predominantly in Inorganic Chemistry, Inorganica Chimica Acta, and Dalton Transactions.
Recent work includes clinical trials for bladder and head-and-neck cancers involving immunotherapy and platinum-based regimens, alongside continued development of organic light-emitting materials and catalytic systems.